Carole Soussain

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 112 publications

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.

Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.

Journal: British journal of haematology

Published: May 05, 2026

Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas.

Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas.

Journal: Journal of neurology

Published: April 27, 2026

CAR T-Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study.

CAR T-Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study.

Journal: American journal of hematology

Published: February 06, 2026

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Journal: Hematological oncology

Published: February 05, 2026

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 21, 2025

Automatic Segmentation of Primary Central Nervous System Lymphoma at Clinical Routine Postcontrast T1-weighted MRI.

Automatic Segmentation of Primary Central Nervous System Lymphoma at Clinical Routine Postcontrast T1-weighted MRI.

Journal: Radiology. Imaging cancer

Published: September 19, 2025

New treatment strategies for primary central nervous system lymphoma.

New treatment strategies for primary central nervous system lymphoma.

Journal: Current opinion in oncology

Published: August 05, 2025

Length of hospital stay and outcome in primary central nervous system lymphoma: a French retrospective multicentric study.

Length of hospital stay and outcome in primary central nervous system lymphoma: a French retrospective multicentric study.

Journal: Annals of hematology

Published: July 14, 2025

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 20, 2025

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 20, 2025

Showing 1-12 of 112

Last Updated: 09/26/2026